Streetbeat News

Revenues

SAVE

Spirit Airlines (NYSE:SAVE) has received 8 analyst ratings in the last three months, showing a diverse range of opinions from indifferent to bearish. The average 12-month price target for SAVE has been adjusted to $3.67, down from $6.28, indicating a 41.56% decrease. Analysts from firms including TD Cowen, Deutsche Bank, Citigroup, Susquehanna, Evercore ISI Group, and Barclays have updated their ratings and price targets, reflecting changes in market conditions and company performance. Spirit Airlines faces challenges in revenue growth, net margin, ROE, ROA, and debt management, with recent financial metrics indicating a decline in revenue and below-industry standards in profitability and asset management.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 7:00 pm

KIDS

OrthoPediatrics (NASDAQ:KIDS) has received mixed analyst ratings over the past quarter, with a recent positive shift in the 12-month price target to $40.29, up 20.88% from $33.33. Analysts from firms like Needham, JMP Securities, and Truist Securities have updated their ratings and price targets, reflecting a bullish to indifferent sentiment. The company, specializing in pediatric orthopedic devices, shows a positive revenue trend with a growth rate of 21.36% as of December 31, 2023, but struggles with profitability, having a net margin of -17.79%. Despite this, its ROE and prudent debt management indicate strong financial performance and a balanced approach to debt.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 7:00 pm

WAT

Waters Corp (NYSE:WAT) reported Q1 2024 sales of $636.8 million, surpassing analyst expectations. Despite a 7% revenue decline, adjusted EPS was $2.21, beating estimates. Sales varied by region, with a notable 18% decrease in Asia. The company expects full-year 2024 sales growth between -0.5% to +1.5% and maintains its adjusted EPS forecast. WAT shares rose 1.88% to $325.59.

Portfolio Pulse from Anusuya Lahiri

May 07, 2024 | 6:55 pm

BNTX

BioNTech (NASDAQ:BNTX) has been evaluated by 12 analysts over the last three months, showing a diverse range of opinions from bullish to bearish. The average 12-month price target for BNTX is now $129.33, up 8.42% from the previous $119.29, with a high estimate of $171.00 and a low of $90.00. Recent analyst actions include adjustments to ratings and price targets, reflecting changes in market conditions and company performance. Despite facing challenges such as a significant revenue decline of -65.43% and lagging behind industry averages in net margin, ROE, and ROA, BioNTech maintains a low debt-to-equity ratio, indicating a conservative financial approach.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 6:01 pm

TGLS

Analysts have provided diverse ratings for Tecnoglass (NYSE:TGLS) over the last three months, with a total of 7 ratings ranging from bullish to indifferent. The average 12-month price target for TGLS has been raised to $57.71, indicating a positive sentiment shift. Key analysts from firms like Baird, B. Riley Securities, DA Davidson, and Stifel have adjusted their price targets and ratings, reflecting their latest outlook on the company. Despite a negative revenue trend and a market capitalization below industry benchmarks, Tecnoglass shows strong financial performance with high net margin, ROE, and ROA, alongside a conservative debt management approach.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 6:01 pm

HIMS

Hims & Hers Health Inc. (NYSE:HIMS) shares rose after reporting Q1 financial results surpassing analyst expectations with a 46% revenue increase to $278.2 million and net income of $11.1 million. The company also provided positive Q2 and full-year revenue guidance above estimates, contributing to its stock price increase.

Portfolio Pulse from Dylan Berman

May 07, 2024 | 5:39 pm

ROOT

Root Inc (NASDAQ:ROOT) was analyzed by 11 analysts, showing a mix of bullish to bearish sentiments. Recent ratings have shifted, with an average 12-month price target of $45.09, marking a 92.69% increase from the previous $23.40. Analysts from firms like Keefe, Bruyette & Woods, Wells Fargo, and JMP Securities have adjusted their ratings and price targets, reflecting optimism in Root's performance. Root's financials indicate a market cap below industry average, a significant revenue growth of 263.62%, but challenges in profitability and debt management.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 5:01 pm

CBT

Four analysts have recently updated their ratings on Cabot (NYSE:CBT), showing a mix of bullish and indifferent stances. The average 12-month price target for CBT has been raised to $102.75, marking a 5.57% increase from the previous target of $97.33. Analysts from UBS, Mizuho, and Deutsche Bank have adjusted their price targets and ratings, reflecting a positive outlook on the company's performance. Despite facing challenges in revenue growth with a -0.73% decline over the last three months, Cabot exhibits strong financial health with impressive net margin, ROE, and ROA figures, alongside a balanced debt approach.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 5:01 pm

VAC

Marriott Vacations (NYSE:VAC) received diverse analyst ratings over the past quarter, with a recent shift towards more bullish views. The average 12-month price target is $119.0, reflecting a 7.79% increase from the previous target of $110.40. Analysts from firms like Stifel, Mizuho, and Truist Securities have adjusted their ratings and price targets, indicating a positive outlook on the company's performance. Marriott Vacations operates in the leisure industry, primarily in the United States, and has shown a positive revenue trend despite a market capitalization below industry averages and challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 5:00 pm

HUN

Analysts have mixed views on Huntsman (NYSE:HUN), with recent evaluations showing a shift towards a more positive outlook. Over the last three months, ratings have varied, but the latest updates indicate an average 12-month price target of $27.5, up 17.02% from the previous target. Key analysts from RBC Capital, Goldman Sachs, and Wells Fargo have raised their price targets, reflecting optimism about the company's performance. Despite a challenging financial landscape with a -8.47% revenue decline and below-average ROE and ROA, Huntsman's strong net margin and low debt-to-equity ratio highlight some financial strengths.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 5:00 pm